Abstract
mice were administered urocortin-2 (30 µg/kg), a peptide which binds exclusively to CRH-R2, or various doses of aqueous TXYF extracts (2.8-11.2 g/kg), a CRH-R2 antagonist Astressin (Ast)2B (20 µg/kg), Ast2B + Ucn2, or Ast2B with various doses of aqueous TXYF extracts for 9 d. Colonic mucosal permeability was then evaluated by measuring the fluorescence intensity in serum. The colitis disease activity index (DAI), histology, body weight loss and colon length were assessed to evaluate the condition of colitis. Terminal deoxynucleotidyl transferase dUTP nick-end labeling was used to detect apoptosis of the intestinal epithelial cells. The expression level of Ki-67 represented the proliferation of colonic epithelial cells and was detected by immunohistochemistry. The expression levels of inflammation cytokines IL-6, TNF-α and CXCL-1 were examined in colon tissues using real-time PCR and ELISA kits.
RESULTS
Compared with the DSS group, mice treated with the CRH-R2 antagonist Ast2B showed greater loss of body weight, shorter colon lengths (4.90 ± 0.32 vs 6.21 ± 0.34 cm, P < 0.05), and higher DAI (3.61 ± 0.53 vs 2.42 ± 0.32, P < 0.05) and histological scores (11.50 ± 1.05 vs 8.33 ± 1.03, P < 0.05). Additionally, the Ast2B group showed increased intestinal permeability (2.76 ± 0.11 µg/mL vs 1.47 ± 0.11 µg/mL, P < 0.001), improved secretion of inflammatory cytokines in colon tissue, and reduced colonic epithelial cell proliferation (4.97 ± 4.25 vs 22.51 ± 8.22, P < 0.05). Increased apoptosis (1422.39 ± 90.71 vs 983.01 ± 98.17, P < 0.001) was also demonstrated. The Ucn2 group demonstrated lower DAI (0.87 ± 0.55 vs 2.42 ± 0.32, P < 0.001) and histological scores (4.33 ± 1.50 vs 8.33 ± 1.03, P < 0.05). Diminished weight loss, longer colon length (9.58 ± 0.62 vs 6.21 ± 0.34 cm, P < 0.001), reduced intestinal permeability (0.75 ± 0.07 vs 1.47 ± 0.11 µg/mL, P < 0.001), inhibited secretion of inflammatory cytokines in colon tissue and increased colonic epithelial cell proliferation (90.04 ± 15.50 vs 22.51 ± 8.22, P < 0.01) were all observed. Reduced apoptosis (149.55 ± 21.68 vs 983.01 ± 98.17, P < 0.05) was also observed. However, significant statistical differences in the results of the Ast2B group and Ast2B + Ucn2 group were observed. TXYF was also found to ameliorate symptoms of DSS-induced colitis in mice and to promote mucosal repair like Ucn2. There were significant differences between the Ast2B + TXYF groups and the TXYF groups.
INTRODUCTION
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis (UC), are a group of chronic inflammatory disorders of the gastrointestinal tract, characterized by intestinal inflammation and mucosal damage [1] . In traditional Chinese medicine theory, UC is known as the "changpi" and chronic dysentery [2] . Characterized by chronic mucosal inflammation and damage of the colon, UC presents with bloody diarrhea, tenesmus, abdominal pain, weight loss, anemia, and even toxic megacolon. Intestinal perforation, intestinal obstruction, intestinal bleeding and cancer are also observed, thus affecting an individual's quality of life [3] . Treatment targets for IBD have changed over the recent years. Previous therapeutic strategies focusing on induction and maintenance of clinical remission have shown no effect on the natural course of the disease [4, 5] . However, in the late 1990s, the advent of biologic agents for the treatment of IBD showed that while patients may be in clinical remission, ongoing mucosal inflammation may still be present, resulting in structural damage [6] [7] [8] [9] [10] [11] . This finding has led to the concept of mucosal healing as a more meaningful therapeutic target in clinical practice. Indeed, emerging data suggests that mucosal healing is strongly associated with a reduction in steroid use, complications, hospitalizations, and surgeries [12] .
Mucosal repair of the intestinal barrier is a tightly coordinated response to injury that preserves homeo stasis and limits the adverse effects of inflammation. After damage to the epithelial tissue, intestinal epithelial cells migrate to the site of injury in a critical process known as epithelial restitution [1315] . Restitution is fo llowed by epithelial cell proliferation and differentiation which is regulated by factors that promote cell viability and limit apoptosis [14, 16] . IBD is a chronic relapsing inflammatory disorder that involves a defective epithelial barrier [17] . Corticotropinreleasing hormone (CRH), the primary mediator of the stress response, is expressed in both the central nervous system and the periphery, including the intestine [18] . The CRH family of peptides interacts with a variety of cell types in the intestinal mucosa, including epithelial cells, enteric neurons, and immune cells [19] . In addition to CRH, three distinct peptides known as urocortins (Ucn1, Ucn2, and Ucn3) bind to two types of G proteincoupled receptors to exert their effects, CRH receptor (R)1 and CRHR2. Yet, Ucn1 has greater affinity for CRHR2 than CRHR1, and Ucn2 and Ucn3 bind exclusively to CRHR2 [20] . Interactions between CRHRs and their ligands modulate several functional and pathophysiologic responses within the gut, including stressinduced alterations in motility, ion secretion, and visceral pain, and the development and maintenance of intestinal inflammation [21] . Studies from others have found that CRH may be involved in the maintenance of intestinal barrier integrity by regulating autophagy in the intestinal epithelial cells [18] . Our previous studies have also found that CRH could cause an increase in intercellular permeability in the intestinal epithelium [22] . Some studies have found that CRHR2 can activate the antiinflammatory response of intestinal mucosa and exert an antiinflammatory effect [23] . In addition, activation of CRHR2 can promote the migration and proliferation of colon cancer cells and gastric mucosa cells [24, 25] . Furthermore, the expression of CRHR2 was found to be downregulated in the biopsy specimens of UC patients [26] and CRHdeficient mice are unable to initiate healing responses after acute experimental colitis [27] , suggesting a role for the CRH peptide family, especially CRHR2, in mucosal repair mechanisms.
TongXieYaoFang (TXYF) is a prescription in traditional Chinese medicine, used for relieving abdo minal pain and diarrhea. TXYF has also been shown to be involved in the reconstruction of the intestinal epithelial barrier and to promote the healing of mucosa in UC [28, 29] . While the mechanism is not understood, it is thought to target and intervene with CRHR2. This regulates the migration, proliferation and apoptosis of epithelial cells, like the role of Ucn2 [30, 31] . The overall aim of the present investigation was to determine whether CRHR2 regulates mucosal repair on dextran sulfate sodium (DSS)induced colitis in mice and to examine the relationship between TXYF and CRHR2 signaling.
MATERIALS AND METHODS

TXYF composition and dosage preparation
TXYF was prepared with large head atractylodes rhizome (Rhizoma Atractylodis Macrocephalae), white peony root (Radix Paeoniae Alba), dried tangerine peel (Pericarpium Citri Reticulatae) and divaricate saposhnikovia root (Radix Saposhnikoviae) [32] , which were used in a 15:12:6:10 proportion. Raw components were soaked in an 8fold volume of distilled water for 1 h and boiled twice for 0.5 h each time. Two of the boiled ingredients were filtered, mixed together, concentrated at a 1:1 ratio (100% concentration), and stored at 4 ℃ for later use.
Animal modeling and drug treatment
Male CD1(ICR) mice (810 wk old) were purchased from Shanghai Xipuerbikai Experimental Animal Co., Ltd., (Shanghai, China) and housed 1 wk under a 12 h light/dark cycle at 2224 ℃ with 50%60% humidity and a noise level < 50 d. Prior to experimentation, mice were allowed free access to food and tap water. All the procedures involving animals were conducted in accordance with the ethical principles adopted by the Animal Experimental Center of Zhejiang Chinese Medical University and were approved by the Ethics Committee on Animal Experiments at Zhejiang Chinese Medical University.
Mice (n = 110) were randomized into 11 assigned groups as follows: control group (n = 10), DSS group (n = 10), DSS + Astressin (Ast)2B group (Ast2B group; n = 10), DSS + Ucn2 group (Ucn2 group; n = 10), DSS + Ast2B + Ucn2 group (Ast2B + Ucn2 group; n = 10), DSS + Ast2B + lowdose (2.8 g/kg•d) aqueous TXYF extract group (Ast2B + TXYFL group; n = 10), DSS + Ast2B + mediumdose (5.6 g/kg•d) aqueous TXYF extract group (Ast2B + TXYFM group; n = 10), DSS + Ast2B + highdose (11.2 g/kg•d) aqueous TXYF extract group (Ast2B + TXYFH group; n = 10), DSS + lowdose (2.8 g/kg•d) aqueous TXYF extract group (TXYFL group; n = 10), DSS + mediumdose (5.6 g/kg•d) aqueous TXYF extract group (TXYFM group; n = 10), and DSS + highdose (11.2 g/kg•d) aqueous TXYF extract group (TXYFH group; n = 10). Colitis was induced in mice by administering 3% (w/v) DSS (MP Biomedicals, Inc., Aurora, OH, United States) in 
In vivo intestinal permeability
The intestinal permeability was measured by de termination of the amount of FITCdextran (molecular weight 4.0 kDa; SigmaAldrich) in blood after oral administration, as described previously [36] . Briefly, mice were fasted overnight and FITCdextran solution (4 kDa, 600 mg/kg) was administered. Blood samples were obtained after 3 h, centrifuged at 10000× rpm for 5 min, and serum was collected. Serum levels of FITC were read at 483 nm and 525 nm on a full wavelength multifunctional enzyme spectrometer (Varioskan Flash, Thermo Fisher Scientific, Waltham, MA, United States).
Real-time quantitative PCR
RNAiso Plus (9108; Takara Bio, Inc., Shiga, Japan) was used to extract RNA from frozen tissue samples, and the concentration of RNA was measured using a trace nucleic acid analyzer (Thermo Fisher Scientific). RNA was reversetranscribed to cDNA using a PrimeScript RT reverse transcription kit (RR036A; Takara Bio, Inc.). Quantitative realtime PCR was carried out by ABI 7500 realtime PCR system (7500; Applied Biosystems of Thermo Fisher Scientific). Primers were designed and synthesized by Shenggong Biology and Engineering Co., Ltd. (Shanghai, China) ( Table 3) . βactin was used as the normalization control, and the 2 ΔΔCT method was used to calculate the relative expression of target genes. 
TNF-α, CXCL-1 and IL-6 measurement
Disease activity index
Intestinal disease activity was assessed based on weight loss, the presence of diarrhea accompanied by blood and mucus, and colonic shortening [33] . DAI was calculated by scoring weight loss, diarrhea and rectal bleeding, based on a previous scoring system ( Table 1) described by Murthy et al [34] with little modification. Weight loss was defined as the difference between the initial and final weights. Diarrhea was defined by the absence of fecal pellet formation and the presence of continuous fluid fecal material in the colon. Rectal bleeding was assessed based on the presence of diarrhea containing visible blood and on the presence of gross rectal bleeding, and was scored as diarrhea. Disease activity index (DAI) values were calculated using the following formula: DAI = [(weight loss score) + (diarrhea score) + (rectal bleeding score)]/3. The clinical parameters used in the present study were chosen to represent the subjective clinical symptoms observed in human UC.
Histological process
Sections of colon fixed in 10% formalin, paraffin embedded and stained with hematoxylin and eosin were used for histological scoring. The sections were graded by two blinded investigators, using a range from 0 to 3 as to amount of inflammation (acute and chronic) and depth of inflammation and with a range from 0 to 4 as to the amount of crypt damage or regeneration, as indicated in Table 2 [35] . These changes were also quantified as to the percent involvement by the disease process: (1) 1%25%; (2) 26%50%; (3) 51%75%; (4) 76%100%. Histological score was calculated using the following formula: histological colitis score = inflammation + depth of lesions + destruction of crypt + width of lesions. TNF-α: Tumor necrosis factor-alpha; CXCL-1: Chemokine (C-X-C motif) ligand-1; IL-6: Interleukin-6; β-actin: Beta-actin.
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China), respectively. All assays were conducted by following the manufacturer's instruction.
Statistical analysis
All analyses were performed using SPSS 24.0 statistical software (IBM Corp., Armonk, NY, United States).
Comparisons between groups were performed using oneway analysis of variance (ANOVA), followed by Scheffe post hoc test for multiple comparisons, other wise a Dunnett's T3 method was used. All data are expressed as the mean ± SD. P < 0.05 was considered statistically significant.
RESULTS
Inhibition of CRH-R2 signaling aggravates the symptoms of DSS-induced colitis in mice
We first assessed the involvement of CRHR2 signaling in mucosal repair after colitis by administering the CRHR2 antagonist Ast2B to mice after induction of DSS colitis. Mice received an intraperitoneal injection of Ast2B daily for 9 d after withdrawal of DSS, and body weight loss, DAI, colon length and histological score were monitored. Compared with the DSS group, mice treated with the CRHR2 antagonist Ast2B showed more body weight loss (P < 0.05) ( Figure 1A ) and shorter colon lengths (4.90 ± 0.32 cm vs 6.21 ± 0.34 cm, P < 0.05) ( Figure 1B) . DAI score and histological score were used to evaluate the severity of UC in mice. The mice in the Ast2B group exhibited significantly higher DAI scores (3.61 ± 0.53 vs 2.42 ± 0.32, P < 0.05) ( Figure 1D ) and histological scores (11.50 ± 1.05 vs 8.33 ± 1.03, P < 0.05) ( Figure 1E ) compared to the mice in the DSS group.
Interestingly, mice treated with Ucn2 after DSS induced colitis showed a smaller degree of body weight loss (P < 0.001) ( Figure 1A ), longer colon length (9.58 ± 0.62 cm vs 6.21 ± 0.34 cm, P < 0.001) (Figure 1B ), lower DAI (0.87 ± 0.55 vs 2.42 ± 0.32, P < 0.001) ( Figure 1D ) and improved histological scores (4.33 ± 1.50 vs 8.33 ± 1.03, P < 0.05) ( Figure 1E ) compared to the mice in the DSS group. However, a significant statistical difference was found between the Ast2B + Ucn2 group and the Ucn2 group ( Figure 1AF ).
Inhibition of CRH-R2 signaling increases secretion of inflammatory cytokines in colon tissues of DSS-induced UC mice
The levels of proinflammatory factors such as TNFα, CXCL1 and IL6 in mouse colon tissues were detected by real timePCR and ELISA. Compared with the DSS group, the Ast2B group showed significantly up regulated mRNA expression of TNFα (6.19 ± 0.51 vs 3.87 ± 0.98, P < 0.05) (Figure 2A However, compared with the DSS group, the Ucn2 group showed significantly decreased mRNA expression of TNFα (Figure 2A ), CXCL1 ( Figure 2B ) and IL6 ( Figure 2C) . Simultaneously, the Ucn2 group demonstrated reduced protein expression of TNFα ( Figure 2D ), CXCL1 ( Figure 2E ) and IL6 ( Figure  2F ). Interestingly, the Ast2B + Ucn2 group showed drastically increased mRNA and protein expression of TNFα, CXCL1 and IL6 compared with the Ucn2 group (P < 0.05 for all).
Inhibition of CRH-R2 signaling promotes intestinal permeability in DSS induced colitis
To determine the effect of CRHR2 signaling on epithelial permeability, we analyzed intestinal permeability in DSS induced colitis model by measuring the concentration of the serum FITC. The concentration of serum FITC dextran was higher in the Ast2B group than DSS group (2.76 ± 0.11 µg/mL vs 1.47 ± 0.11 µg/mL, P < 0.05) (Figure 3) . However, the concentration of serum FITC dextran in the Ucn2 group was lower than DSS group (0.75 ± 0.07 µg/mL vs 1.47 ± 0.11 µg/mL, P < 0.05) (Figure 3 ). An obvious difference was observed between the Ast2B+Ucn2 group and the Ucn2 group.
Inhibition of CRH-R2 signaling promotes colonic epithelial cell apoptosis and reduces epithelial cell proliferation
The effect of Ast2B on cell proliferation and cell death was then determined. TUNEL staining was significantly increased in the Ast2B group compared with the DSS group (1422.39 ± 90.71 vs 983.01 ± 98.17, P < 0.001) ( Figure 4L ). At the same time, the Ast2B group showed significantly decreased cell proliferation (4.97 ± 4.25 vs 22.51 ± 8.22, P < 0.05) ( Figure 5L) . Interestingly, the Ucn2 group showed promoted colonic epithelial cell proliferation ( Figure 5L ) and reduced epithelial cell apoptosis ( Figure 4L ). However, significant statistical differences were found between the Ucn2 group and the Ast2B + Ucn2 group with regards to colonic epithelial cell apoptosis and proliferation (P < 0.01 for both).
TXYF promotes mucosal repair in colitis mice by regulating CRH-R2 signaling
To obtain insight into the underlying mechanism re sponsible for promoting mucosal repair of TXYF, DSS induced colitis mice were pretreated with the CRHR2 antagonist Ast2B, and later treated with various doses of aqueous TXYF extracts.
Compared with the DSS group, the TXYFH groups had lower DAI scores ( Figure 1D ) and histological scores ( Figure 1E ), and decreased body weight loss ( Figure 1A) . TXYFM,H groups, on the other hand, had longer colon length ( Figure 1B ) and improved intestinal permeability (Figure 3) . Furthermore, TXYF inhibited secretion of inflammatory cytokines in colon tissues ( Figure 2AF ) and promoted colonic epithelial cell proliferation ( Figure 5L ), along with reducing apoptosis ( Figure 4L ). However, the Ast2B + TXYF groups showed significant statistical difference in DAI, body weight loss, colon length and histological scores, when compared with the TXYF groups. As for inhibiting secretion of inflammatory cytokines, the Ast2B + TXYF groups demonstrated significant differences within the TXYF groups. Additionally, the Ast2B + TXYF groups showed markedly improved intestinal permeability in DSSinduced colitis compared with the TXYF groups, respectively. In addition, the Ast2B + TXYF groups demonstrated significant differences with the TXYF groups in promoting colonic epithelial cell proliferation and reducing epithelial cell apoptosis.
These results further confirm the idea that CRHR2 signaling is the main mechanism of TXYFmediated mucosal repair in DSSinduced colitis in mice.
DISCUSSION
Mucosal healing is a desired therapeutic endpoint in the treatment of IBD; interventions that promote restoration of the epithelial barrier are needed to limit inflammation and to prevent future injury. Mucosal hea ling consists of two processes [15] . Firstly, intact cells in the adjacent region migrate to the injured area; then, the cells compensate for damaged cells by proliferation and help to maintain normal thickness of the intestinal epithelium. Therefore, the migration and proliferation of intestinal epithelial cells are the key mechanisms for the healing of epithelial defects after mucosal injury. In addition, inhibiting apoptosis of intestinal epithelial cells can promote the healing process of mucosa [37] . It is well known that intestinal epithelial barrier defects are Data are presented as mean ± standard deviation, n = 6 per group. a P < 0.001 vs control group; g P < 0.05, b P < 0.001 vs DSS group; e P < 0.001 vs Ucn2 group; f P < 0.001 vs TXYF-L group; d P < 0.001 vs TXYF-M group; c P < 0.001 vs TXYF-H group. CRH-R2: Corticotropin-releasing hormone-receptor 2; DSS: Dextran sulfate sodium; TXYF: Tong-Xie-Yao-Fang.
characterized by increased intestinal permeability.
In the present study, it was found that selective inhibition of CRHR2 signaling can aggravate symptoms of DSSinduced colitis, destroy the impaired intestinal barrier function, promote colonic epithelial cell apoptosis and reduce epithelial cell proliferation. After treatment with Ucn2 and TXYF, DSSinduced mice demonstrated ameliorated symptoms of DSSinduced colitis, improved impaired intestinal barrier function, promoted colonic epithelial cell proliferation and reduced epithelial cell apoptosis. Moreover, Ucn2 and TXYF reduced the expression of the proinflammatory factors TNFα, CXCL1, and IL6 in colon tissues.
Cytokines play a central role in the regulation of both intestinal inflammation and mucosal repair mechanisms [38] . Treatments that neutralize the proinflammatory actions of TNFα promote mucosal healing and are a standard of current IBD treatment paradigms [7, 38] . In addition, production of the key proinflammatory cytokine IL6 correlates with the degree of active intestinal inflam mation in IBD patients [39] , further supporting the concept that therapeutic interventions that modulate cytokine production and/or release may promote mucosal repair after inflammation. Taken together, these results indicate that Ucn2 and TXYF promote mucosal repair.
Studies from others have found that CRH may be involved in the maintenance of intestinal barrier integrity by regulating autophagy in the intestinal epithelial cells [18] . Our previous studies also found that CRH could induce an increase in intercellular permeability in the intestinal epithelium [22] . Some studies have also found that CRHR2 can activate the antiinflammatory response of intestinal mucosa and exert an antiinflammatory effect [23] . In addition, activation of CRHR2 can promote the migration and proliferation of colon cancer cells and gastric mucosa cells [24, 25] . Furthermore, the expression of CRHR2 has been reported as downregulated in biopsy specimens of UC patients [26] and CRHdeficient mice have been reported as unable to initiate healing responses after acute experimental colitis [27] . These results suggest a role for the CRH peptide family, especially CRHR2, in mucosal repair mechanisms. It is known that Ucn2 is a peptide which binds exclusively to CRHR2. Significant statistical differences were found between the Ast2B group and the Ast2B + Ucn2 group. Thus, a conclusion can be made that CRHR2 activated the intestinal mucosal antiinflammatory response by regulating the migration, proliferation and apoptosis of intestinal epithelial cells in colitis mice.
Subsequently, the efficacy of TXYF was assessed.
According to the theory of traditional Chinese medicine, IBD belongs to "diarrhea, dysentery". The principle of treatment is focused on relieving pain and eliminating dampness and diarrhea. TXYF is a classic formula in the Jing yue quan shu (Jingyue's Complete Book), which consists of atractylodes rhizome (Rhizoma Atractylodis Macrocephalae) head groups, white peony root (Radix Paeoniae Alba), dried tangerine peel (Pericarpium Citri Reticulatae), and divaricate saposhnikovia root (Radix Saposhnikoviae). TXYF has been believed to be effective in improving disorders of the digestive system and alleviating abdominal pain, diarrhea, and has been used widely as a medication to treat inflammatory bowel syndrome and UC clinically, without inducing hepatomegaly or splenomegaly [4042] . TXYF has also been shown to improve reconstruction P < 0.01 vs control group; a P < 0.05, b P < 0.01 vs DSS group. f P < 0.01 vs Ucn2 group; e P < 0.05 vs TXYF-L group; g P < 0.01 vs TXYF-M group; h P < 0.01 vs TXYF-H group. CRH-R2: Corticotropin-releasing hormone-receptor 2; DSS: Dextran sulfate sodium; TXYF: Tong-Xie-Yao-Fang.
of the intestinal epithelial barrier and promote the healing of mucosa in UC [28, 29] . Our previous study found that TXYF downregulated CRHR1 and upregulated CRHR2. While the mechanism underlying TXYF pro motion of mucosal repair is not well understood, it is thought to intervene using CRHR2 and to regulate the migration, proliferation and apoptosis of epithelial cells, like the role of Ucn2 [30, 31] . Herein, we describe the selective inhibition of CRHR2 signaling in the intestinal mucosa of mice after experimental colitis, along with TXYF treatment, leading to exacerbated symptoms of DSSinduced colitis, delayed healing, increased expression of proinflam matory factors TNFα, CXCL1 and IL6 in colon tissues, decreased epithelial cell proliferation and promoted cell apoptosis. These results suggest that TXYF promoted the mucosal repair process of colitis mice by regulating CRHR2.
In conclusion, CRHR2 activates the intestinal mucosal antiinflammatory response by regulating the migration, proliferation and apoptosis of intestinal epithelial cells in colitis mice, and exerts an antiinflammatory effect. The effects of TXYF on the mucosal repair process are focused on regulating CRHR2 in colitis mice.
ARTICLE HIGHLIGHTS
Research background
Mucosal healing is a desired therapeutic end-point in the treatment of inflammatory bowel disease (IBD). However, thorough treatment of IBD is difficult and there are some adverse reactions. According to studies, corticotropin-releasing hormone (CRH)-receptor (R)2 can activate the inflammatory response of intestinal mucosa. Our preliminary study found that Tong-Xie-Yao-Fang could lower CRH-R1, increase the expression of CRH-R2, and participates in reconstruction of the intestinal barrier.
Research motivation
Mucosal healing is a desired therapeutic end-point in the treatment of IBD. However, the mechanism of mucosal healing is still unclear.
Research objectives
To explore the significance of CRH-R2 in the mucosal healing of dextran sulfate sodium (DSS)-induced colitis and study the effect of Tong-Xie-Yao-Fang (TXYF) on CRH-R2.
Research methods
Ulcerative colitis (UC) was induced in mice by administration of 3% (w/v) DSS for 7 d. Then, mice were administered urocortin (Ucn)-2 or various doses of aqueous TXYF extracts, the CRH-R2 antagonist Astressin (Ast)2B, Ast2B + Ucn2, or Ast2B with various doses of aqueous TXYF extracts for 9 d. The colitis disease activity index (DAI) was assessed to evaluate the condition of colitis. The expression level of Ki-67 represented the proliferation of colonic epithelial cells. The expression levels of inflammation cytokines IL-6, TNF-α and CXCL-1 were examined by PCR and enzyme-linked immunosorbent assay.
Research results
Compared with the DSS group, mice treated with the CRH-R2 antagonist Ast2B showed greater loss of body weight, shorter colon lengths, and higher DAI and histological scores. Additionally, the Ast2B group showed increased intestinal permeability, improved secretion of inflammatory cytokines in colon tissue and reduced colonic epithelial cell proliferation. Increased apoptosis was also demonstrated. The Ucn2 group demonstrated lower DAI and histological scores. Diminished weight loss, longer colon length, reduced intestinal permeability, inhibited secretion of inflammatory cytokines in colon tissue and increased colonic epithelial cell proliferation were all observed. Reduced apoptosis was also observed.
Research conclusions
CRH-R2 activates the intestinal mucosal antiinflammatory response and plays an important antiinflammatory role. TXYF promotes the mucosal repair process in colitis mice.
Research perspectives
The CRH-R2 signaling pathway plays a pivotal role in mucosal healing in experimental UC in mice. Mucosal healing is a desired therapeutic end-point in the treatment of IBD. Thus, the findings of this study indicate a new potential mechanism by which CRH-R2 treats UC. TXYF, which has fewer side effects than other medicines, promotes the mucosal repair process of colitis mice by regulating CRH-R2. Therefore, TXYF can be used in patients with UC to promote their mucosal repair.
